Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for rapid antidepressant response in depression comorbid with cancer
2024-517747-31-00Phase 2Authorised
- Sponsor
- National Institute of Mental Health, Czech Republic
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin, ketamine and midazolam in major depressive disorder (MDD) (5 arms), sponsored by National Institute of Mental Health, Czech Republic. Primary endpoint: Antidepressant efficacy by MADRS. Planned start Jul 2022; status: authorised.
02
Drugs
psilocybinketaminemidazolam
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-517747-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517747-31-00.